Merus BV Company Insiders
| MRUS Stock | USD 53.82 0.49 0.92% |
Merus BV employs about 260 people. The company is managed by 17 executives with a total tenure of roughly 607 years, averaging almost 35.0 years of service per executive, having 15.29 employees per reported executive. Breaking down Merus BV's management performance can provide insight into the firm performance.
Merus BV Management Team Effectiveness
The company has return on total asset (ROA) of (0.3061) % which means that it has lost $0.3061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5866) %, meaning that it created substantial loss on money invested by shareholders. Merus BV's management efficiency ratios could be used to measure how well Merus BV manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Merus BV's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 224.3 M in 2025, whereas Other Assets are likely to drop slightly above 1.3 M in 2025.Common Stock Shares Outstanding is likely to drop to about 32.4 M in 2025. Net Loss is likely to gain to about (112.2 M) in 2025
Merus BV Workforce Comparison
Merus BV is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 173,573. Merus BV adds roughly 260 in number of employees claiming only tiny portion of equities under Health Care industry.
Merus BV Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merus BV insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merus BV's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Merus BV insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Silverman Peter B. over two weeks ago Disposition of 34000 shares by Silverman Peter B. of Merus BV at 52.76 subject to Rule 16b-3 | ||
Harry Shuman over three months ago Disposition of 1000 shares by Harry Shuman of Merus BV at 18.61 subject to Rule 16b-3 | ||
Harry Shuman over three months ago Disposition of 1000 shares by Harry Shuman of Merus BV at 24.43 subject to Rule 16b-3 | ||
Hui Liu over three months ago Acquisition by Hui Liu of 98085 shares of Merus BV at 7.86 subject to Rule 16b-3 | ||
Zohren Fabian over three months ago Acquisition by Zohren Fabian of 50000 shares of Merus BV at 41.65 subject to Rule 16b-3 | ||
Harry Shuman over six months ago Disposition of 1000 shares by Harry Shuman of Merus BV at 18.61 subject to Rule 16b-3 | ||
Harry Shuman over six months ago Disposition of 7300 shares by Harry Shuman of Merus BV at 57.84 subject to Rule 16b-3 | ||
Haddock Jason over six months ago Acquisition by Haddock Jason of 17688 shares of Merus BV at 48.73 subject to Rule 16b-3 |
Merus BV Notable Stakeholders
A Merus BV stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Merus BV often face trade-offs trying to please all of them. Merus BV's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Merus BV's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Hui Liu | Chief Business Officer and Head of Merus U.S., Executive Vice President | Profile | |
| Peter JD | Company EVP | Profile | |
| Ashley PharmD | Senior Affairs | Profile | |
| Kathleen Farren | IR Officer | Profile | |
| Gregory Perry | Chief Officer | Profile | |
| Ernesto MD | Senior Development | Profile | |
| Hennie Hoogenboom | CoFounder Advisor | Profile | |
| Alexander Bakker | Chief VP | Profile | |
| Cecilia Geuijen | Chief VP | Profile | |
| Jillian Connell | VP Communications | Profile | |
| Sven MD | President, CEO | Profile | |
| Fabian MD | Chief Officer | Profile | |
| Cornelis Kruif | CTO VP | Profile | |
| Harry Shuman | Chief Officer | Profile | |
| Andrew MD | Consultant | Profile | |
| Audrey Bergan | Chief Officer | Profile | |
| Shannon Campbell | Executive Officer | Profile |
About Merus BV Management Performance
The success or failure of an entity such as Merus BV often depends on how effective the management is. Merus BV management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Merus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Merus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Merus NV is traded on NASDAQ Exchange in the United States.
Please note, the imprecision that can be found in Merus BV's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Merus BV. Check Merus BV's Beneish M Score to see the likelihood of Merus BV's management manipulating its earnings.
Merus BV Workforce Analysis
Traditionally, organizations such as Merus BV use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Merus BV within its industry.Merus BV Manpower Efficiency
Return on Merus BV Manpower
| Revenue Per Employee | 139K | |
| Revenue Per Executive | 2.1M | |
| Net Loss Per Employee | 828.2K | |
| Net Loss Per Executive | 12.7M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 28.4M |
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.